Latest News and Press Releases

The Rwanda FDA has given regulatory approval to GreenLight to start a Phase I/II clinical trial of its Covid-19 vaccine candidate in Rwanda. This phase I/II clinical trial is the first step in...

The effort will combine GreenLight’s mRNA design and manufacturing expertise with EpiVax’s advanced Ancer® pipeline for personalized cancer vaccine designEpivax Therapeutics, Inc. will contribute a...

Working toward clinical trial initiation for COVID vaccine candidate in 2023Shingles vaccine candidate selection planned for 2023 in partnership with Serum Institute of IndiaCalantha™, Colorado potato...

BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the potential of RNA to address some of the world’s toughest...

BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to bring effective and safe solutions to make food clean and affordable for...

GreenLight Biosciences and Queensland University of Technology (QUT) partner to create a solution for fall armywormFall armyworm is one of the most destructive insect pests on the planet, causing more...

GreenLight raised $108.4 million in private placement led by S2G Ventures with strong participation from existing and new investors with cash expected to fund critical programs through the first half...

BOSTON, Aug. 12, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to bring effective and safe solutions to make food clean and affordable for...

GreenLight’s messenger RNA production process is transferable to large-scale equipment and CMO facilities​Technology transfer and scale-up from lab bench to Samsung’s commercial facility was completed...

BOSTON, July 29, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences has announced a collaboration with the National Institutes of Health (NIH) to develop COVID-19 vaccines that are more broadly...